# A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

> **NCT07745504** · PHASE3 · RECRUITING · sponsor: **Novo Nordisk A/S** · enrollment: 285 (estimated)

## Conditions studied

- Overweight
- Obesity

## Interventions

- **DRUG:** Cagrilintide
- **DRUG:** Placebo cagrilintide
- **DRUG:** Placebo semaglutide

## Key facts

- **NCT ID:** NCT07745504
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-04
- **Primary completion:** 2027-05-18
- **Final completion:** 2027-07-06
- **Target enrollment:** 285 (ESTIMATED)
- **Last updated:** 2026-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07745504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07745504, "A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07745504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*